subscribeSubscribe
Annora`s Generic Glycerol Phenylbutyrate Receives Approval in the U.S.

Annora`s Generic Glycerol Phenylbutyrate Receives Approval in the U.S.
FDA
09 Aug 2022
Share Share
The top 10 most-expensive meds in the U.S.—and they`re not the usual suspects

The top 10 most-expensive meds in the U.S.—and they`re not the usual suspects
Eric Sagonowsky FIERCE PHARMA
13 Jun 2019
Share Share
Horizon Pharma Announces FDA Approval of RAVICTI® (glycerol phenylbutyrate) Oral

Horizon Pharma Announces FDA Approval of RAVICTI® (glycerol phenylbutyrate) Oral
BUSINESSWIRE
28 Dec 2018
Share Share
Sobi secures NHS reimbursement for Ravicti

Sobi secures NHS reimbursement for Ravicti
Selina McKee PHARMA TIMES
23 Aug 2018
Share Share
Raviciti® (glycerol phenylbutyrate) : Horizon Therapeutics v. Par Pharmaceutical

Raviciti® (glycerol phenylbutyrate) : Horizon Therapeutics v. Par Pharmaceutical
PATENT LITIGATION
11 Aug 2018
Share Share
Horizon Pharma Announces USPTO Issuance Covering Ravicti Oral Liquid

Horizon Pharma Announces USPTO Issuance Covering Ravicti Oral Liquid
BUSINESSWIRE
17 Jul 2018
Share Share
Horizon Announces the U.S. Patent & Trademark inssue notice RAVICTI® Oral Liquid

Horizon Announces the U.S. Patent & Trademark inssue notice RAVICTI® Oral Liquid
PRESS RELEASE
16 Jul 2018
Share Share
With FDA nod, BioMarin prices orphan drug Brineura at $702,000

With FDA nod, BioMarin prices orphan drug Brineura at $702,000
Eric Sagonowsky FIERCE PHARMA
28 Apr 2017
Share Share
Sobi & Horizon enter five-year distribution agreement for Ravicti & Ammonaps

Sobi & Horizon enter five-year distribution agreement for Ravicti & Ammonaps
PR NEWSWIRE
07 Dec 2016
Share Share
More Rare Disease Deal making to Follow Horizon`s Raptor Deal

More Rare Disease Deal making to Follow Horizon`s Raptor Deal
Sarah Pringle THE STREET
13 Sep 2016
Share Share